BALTIMORE, Sept. 2, 2026 /PRNewswire/ -- Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects of the knee, today announced the successful treatment of the first patient in its First-in-Human (FIH) clinical study.
Nanochon Performs First Case in the Chondrograft™ First in Human Clinical Study
2 min read Premium comments
NanochonChondrograftarticular cartilage defectsknee defectsFirst-in-Human clinical study
The study is designed to evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee. Dr. Juan Osorio and Dr. Emilio Tufiño, who both specialize in regenerative sports medicine, performed the first procedure at The Panama Clinic, Panamá.
"I am pleased to be the Principal Investigator for this important study, and we are excited to be the first to initiate clinical study enrollment. The team here in Panamá looks forward to contributing the data that will support a larger clinical study and subsequent market entry," stated Dr. Osorio.
"The speed at which Dr. Osorio and the clinical team were able to identify, enroll, and treat the first patient underscores the significant unmet clinical need in cartilage repair," said Ben Holmes, Co-Founder and Chief Executive Officer of Nanochon. "This milestone marks an important step forward for Nanochon as we continue generating the clinical evidence required to support a future Level 1 pivotal study.
"The procedure is bone-sparing, minimally invasive, and streamlined, and the dedicated instrumentation set made the procedure simple and efficient," stated Dr. Tufiño.
The prospective FIH study will enroll patients between the ages of 22 and 60 who have failed conservative treatment options and present with one or two femoral condyle and/or trochlear cartilage lesions.
Articular cartilage injuries remain one of the most challenging conditions in orthopedic medicine, often leading to chronic pain, reduced mobility, and progressive joint degeneration. Current treatment approaches can involve lengthy rehabilitation periods and frequently do not restore durable, functional cartilage tissue.
"Developing a solution that enables the body to regenerate durable cartilage with the strength and function of native tissue has long been considered one of the holy grails of orthopedic medicine," said R. Sean Churchill, MD, MBA, Managing Director of cultivate(MD).
"Nanochon's preclinical work has demonstrated highly encouraging results, and we are excited to see this technology now being evaluated in human patients."
Chondrograft™ is designed to provide immediate mechanical support, be minimally invasive, and a "burn-no-bridges" solution for "pre-replacement" patients — those with cartilage damage who need more than temporary relief but aren't yet candidates for joint replacement.
"Our vision is to fundamentally change the treatment paradigm for cartilage injuries and potentially delay or eliminate the need for revision surgery and knee replacement procedures in younger patients," said Nathan Castro, Co-Founder and Chief Technology Officer of Nanochon. "We believe Chondrograft™ has the potential to provide physicians with a simpler, more effective approach to cartilage treatment."
Following completion of the FIH study, Nanochon plans to initiate a Level 1 multi-center, randomized, controlled, pivotal clinical trial.
About Nanochon
Nanochon, Inc. is a medical device company developing innovative solutions for cartilage repair in patients who are not yet candidates for joint replacement. The company's lead technology, Chondrograft™, is designed to address focal cartilage defects through a minimally invasive regenerative approach. Nanochon has received Breakthrough Device Designation from the U.S. Food and Drug Administration.
Media Contact
Rachel Offenburg
Chief of Strategy
Rachel.offenburg@nanochon.com
SOURCE Nanochon
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Nanochon initiated its First-in-Human clinical study for Chondrograft™, a 3D-printed implant targeting articular cartilage defects. This strategy addresses a significant unmet market need for "pre-replacement" patients, aiming to delay or eliminate knee replacement in younger individuals. The minimally invasive, bone-sparing procedure with streamlined instrumentation positions it as a potentially simpler, more effective solution, supported by FDA Breakthrough Device Designation for future market entry and a pivotal trial.
- The company targets a critical market gap for patients with cartilage damage not yet requiring total joint replacement.
- Its minimally invasive approach and streamlined procedure could enhance adoption and reduce healthcare costs.
PhD Lens: Clinical and outcomes impact
Nanochon's Chondrograft™, a novel 3D-printed implant, aims to regenerate durable, native-like cartilage for focal chondral defects of the knee. The First-in-Human study evaluates its safety and performance in patients aged 22-60 who failed conservative treatments. Preclinical work showed encouraging results, and the procedure is designed to be bone-sparing and minimally invasive, addressing a challenging condition where current treatments often fail to restore functional tissue.
- The implant's mechanism focuses on enabling the body's own cartilage regeneration, providing immediate mechanical support.
- The FIH study will gather initial human data on safety and performance for a specific patient demographic.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.